Dapagliflozin is associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all-cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic

29 April 2017 (00:00 - 00:00)

Organised by:

Sign in for access options

About the speaker

Professor Anna Norhammar

Karolinska Institute, Stockholm (Sweden)

8 More presentations in this session

Presentation thumbnail

Systolic heart failure treatment with the if inhibitor ivabradine trial

Professor M. Boehm (Homburg, DE)

Presentation thumbnail

Real-world heart failure treatment in 10.330 patients with chronic heart failure in the netherlands

Professor J. Brugts (Rotterdam, NL)

Presentation thumbnail

Clinical profiles, management and outcome of acute heart failure in Korea: results from the Korean acute heart failure registry (KorAHF)

Professor H. Lee (Seoul, KR)

Presentation thumbnail

Non-invasive lung impedance-guided preemptive treatment in chronic heart failure patients: a randomized controlled trial (IMPEDANCE-HF Trial)

Professor M. Kleiner Shochat (Hadera, IL)

Presentation thumbnail

Single dose, purified biocompatible vegf a mrna administered one week post myocardial infarction in pigs inhibits cardiac fibrosis and leads to chronic reversal of global ventricular dysfunction

Professor K. Chien (Stockholm, SE)

Access the full session

Session thumbnail

Clinical Forum - Sat. 29 April 08:30 - Tues. 02 May at 12:30

The Event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources